Cadila Pharma unveils quadrivalent influenza vaccine Cadiflu Tetra
New Delhi: Cadila Pharmaceuticals has said it has launched a vaccine to prevent influenza, a recurrent and widespread viral infection. The drug firm has introduced quadrivalent Cadiflu Tetra vaccine which has been approved by the DCGI (Drugs Controller General of India) for use in adults and children.
The new vaccine targets four strains of the influenza virus subtype -A and B, responsible for seasonal epidemics, the drug firm said in a statement.
Developed using proprietary technology employing nano-sized particles, the vaccine mimics the external structure of the virus without containing intact genetic material, it added.
Medical Dialogues team had earlier reported that Cadila Pharma has launched the world's first aqueous formulation of cholecalciferol for Vitamin D deficiency.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd